SPONSOR
Clarity Pharmaceuticals Ltd
Total Trials
2
Recruiting
2
Phases
Phase 1, Phase 2, Phase 3
NCT04868604 Phase 1, Phase 2
Recruiting
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Prostatic Neoplasms, Castration-Resistant
NCT06056830 Phase 3
Recruiting
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
Prostate Cancer